BEIJING – The cream of the crop in China's biotech world are quietly but surely developing strategies to bring their innovative assets to global markets. That was the message shared by Rick Sax, global head and senior vice president of clinical trials and reporting at Quintiles Transnational Corp., during the recent China Trials 7 conference, where he discussed what he terms a new China biopharma paradigm.